Adaptimmune

“Adaptimmune will consider granting expanded access to an investigational medicine only if all of the following threshold criteria are met: The illness must be serious or life-threatening with no other satisfactory treatment options (such as approved products or enrolling clinical trials), The patient is ineligible or otherwise unable to participate in a clinical trial, There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks, based on available safety and efficacy information, Ability to provide a product in a fair and equitable manner, so that there is adequate manufacturing capacity for ongoing programs, Whether granting expanded access would potentially compromise the scientific validity of broader development programs, or interfere with or delay current clinical trials or regulatory filings designed to make the therapy available to many more patients.”

In general, patients obtain access to investigational therapies prior to regulatory approval by participating in clinical trials. There may, however, be circumstances when patients with a serious or life-threatening illness have exhausted all available treatment options and are not eligible to participate in any appropriate clinical trials. In those cases, patients may be eligible for treatment with an investigational therapy through programs referred to as ‘Expanded Access Programs’ (EAPs) or ‘compassionate use’. [Click here](https://www.adaptimmune.com/clinical-trials/expanded-access-policy) to read about our policy.

Conditions: Synovial Sarcoma, Myxoid Liposarcoma